Press Release

NEW2024-11-01 Daewoong Pharmaceutical Announces Third Quarter 2024 Financial Results

NEW2024-10-14 Daewoong Pharmaceutical Unveils ‘Innovative Drug Delivery Technologies’ in Milan—From World’s First Microneedle Therapy to Once-a-Month Obesity Treatment

NEW2024-08-09 Daewoong Pharmaceutical Announces Second Quarter 2024 Financial Results

Daewoong Pharmaceutical Announces Third Quarter 2024 Financial Results 2024-11-01
Daewoong Pharmaceutical Unveils ‘Innovative Drug Delivery Technologies’ in Milan—From World’s First Microneedle Therapy to Once-a-Month Obesity Treatment 2024-10-14
Daewoong Pharmaceutical Announces Second Quarter 2024 Financial Results 2024-08-09
Daewoong Pharmaceutical's 'Fexuprazan' Expands into Latin America: Enters $300 Million Market in Mexico, Chile, and Ecuador 2024-08-08
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin 2024-07-29
Daewoong Pharmaceutical Presented Superiority of Enavogliflozin at 84th ADA Scientific Sessions 2024-07-12
Daewoong Presents Enavogliflozin’s Phase 3 Pooled Analysis Results at 84th ADA Conference 2024-06-19
Daewoong Pharmaceutical Reports Q1 2024 Financial Results 2024-04-30
Daewoong Pharmaceutical submits a new drug application (NDA) for Enavogliflozin in Mexico 2024-04-15

이전 페이지 1 / 45다음 페이지

Search